Roles of the Mitogen-activated Protein Kinase Family in Macrophage Responses to Colony Stimulating Factor-1 Addition and Withdrawal*

Anthony JaworowskiDagger , Nicholas J. Wilson, Elizabeth Christy, Robert Byrne, and John A. Hamilton

From the Inflammation Research Centre, University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Colony stimulating factor-1 (CSF-1) (or macrophage CSF) is involved in the survival, proliferation, differentiation, and activation of cells of the monocyte/macrophage lineage. Because the mitogen-activated protein kinase family members extracellular signal-regulated kinases (ERKs), p38, and c-Jun N-terminal kinase are widely implicated in such cellular functions, we measured their activity in growing and growth-arrested cultures of bone marrow-derived macrophages (BMM), as well as their stimulation by saturating concentrations of CSF-1. ERK activity was approximately 2-fold higher in cycling BMM compared with growth-arrested BMM; in addition, CSF-1-stimulated BMM DNA synthesis was partially inhibited by PD98059, a specific inhibitor of MEK activation, suggesting a role for a mitogen-activated protein-ERK kinase (MEK)/ERK pathway in the control of DNA synthesis but surprisingly not in the control of cyclin D1 mRNA or c-myc mRNA expression. The suppression of BMM apoptosis by CSF-1, i.e. enhanced survival, was not reversed by PD98059, suggesting that a MEK/ERK pathway is not involved in this process.

Using a quantitative kinase assay, it was found that CSF-1 gave a slight increase in BMM p38 activity, supporting prior data that CSF-1 is a relatively weak stimulator of inflammatory cytokine production in monocytes/macrophages. Relatively high concentrations of the p38 inhibitor, SKB202190, suppressed CSF-1-stimulated BMM DNA synthesis. No evidence could be obtained for the involvement of p38 activity in BMM apoptosis following CSF-1 withdrawal. We were not able to show that CSF-1 enhanced BMM JNK-1 activity to a significant extent; again, no role could be found for JNK-1 activity in the BMM apoptosis occurring after CSF-1 removal.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In addition to being necessary for proliferation, colony stimulating factor-1 (CSF-1)1 or macrophage CSF is absolutely required for the continued survival of certain populations of cells of the monocyte/macrophage lineage (1). Several lines of evidence suggest that the maintenance of survival and the stimulation of proliferation are mediated by either different signaling pathways activated by the CSF-1 receptor or require different thresholds of activation of similar pathways (2-4). Advances have been made in describing the signal transduction molecules activated in response to CSF-1 stimulation of macrophages, although the details of the pathways leading to their activation are still in many cases unresolved (5). The role of the CSF-1 receptor in controlling passage through the G1 phase of the cell cycle has been relatively well studied, and it has been shown, for example, for cell cycle progression that continued stimulation by CSF-1 is required for the synthesis of D-type cyclins as is the up-regulation of c-myc (6-8). Relatively little, however, is known about the signal transduction pathways activated by CSF-1 involved in maintaining cell survival.

Recent research has suggested roles for different members of the MAP kinase family (ERKs, p38/(CSBP), JNK (stress-activated protein kinase)) in promoting either cell survival and/or proliferation, in response to growth factor stimulation, or apoptosis, in response to various stress stimuli. There are many examples where enhanced ERK activity has been implicated in growth factor-mediated cell survival and/or proliferation (for example, see Ref. 9 for review); significant downstream responses of ERK-dependent signal transduction pathways that have been proposed to be important for cell cycle progression are cyclin D1 and c-myc transcription, including in CSF-1-stimulated NIH-3T3 cells expressing the CSF-1 receptor (c-Fms) (Ref. 10 and references therein). The relationship between ERK activation and other responses in macrophages is, however, much more complicated than the above discussion suggests. In this cell type, activation of ERKs has not been found to correlate strongly with the level of subsequent DNA synthesis (11, 12), and there is some evidence to suggest that there may be Ras-independent control over ERK activity (5). Also, in macrophages, elevated intracellular cAMP enhances CSF-1-stimulated ERK activity while suppressing the corresponding rise in cyclin D1 mRNA, suggesting a possible dissociation (12).

The p38 and JNK cascades are primarily activated by various environmental stresses: proinflammatory cytokines (TNFalpha and interleukin-1), osmotic shock, ultraviolet radiation, heat shock, x-ray irradiation, hydrogen peroxide, and protein synthesis inhibitors (for review, see Ref. 13). They have also been proposed to be involved in the regulation of apoptosis, because, for example, overexpression of kinases that activate them resulted in the induction of apoptosis (14, 15), withdrawal of a growth factor (nerve growth factor) from PC-12 cultures can result in a transient activation of the p38 and JNK families (14), and inhibition of p38 MAP kinase activity can suppress apoptosis (16). Contrary to its role in cellular stress responses, it has recently been reported that CSF-1 activates p38 activity in a myeloid cell line, and a role for this enzyme in hemopoietic cell proliferation was postulated (17). p38 also has a well established role in cytokine production by lipopolysaccharide (LPS)-activated macrophages (18). However, there has been controversy as to whether CSF-1 is a strong stimulator of cytokine production in macrophages relative to stimuli such as LPS (for review, see Ref. 19). Reports from our laboratory and those of others have shown that CSF-1 treatment of monocytes and macrophages does not lead to high levels of secreted proinflammatory cytokine production (19, 20). It is therefore of interest to know whether CSF-1 is a potent stimulator of p38 activity in cells of the macrophage lineage and what the significance of such stimulation may be.

From the above background information, it is clear that the role of the MAP kinase family in cell survival and/or proliferation is cell type- and/or stimulus-specific. It has been maintained before (5) that the relevance of signal transduction pathways to the cell biology of a growth factor such as CSF-1 must be analyzed in each individual case and is best studied in cells where the receptor (c-Fms) is normally expressed and preferably in primary cultures of such cells rather than in immortalized cell lines, where proliferation and survival pathways are, ipso facto, altered. We therefore have examined the roles of the MAP kinase family members, including potentially dependent pathways, in CSF-1-treated murine bone marrow-derived macrophages (BMM); because BMM depend upon CSF-1 for survival (1), we also examined the activities of the MAP kinase family members upon CSF-1 withdrawal. We report evidence for some involvement of ERK activity in CSF-1-stimulated BMM DNA synthesis but, interestingly, and in contrast to reports in fibroblasts ectoptically expressing c-fms, no evidence for its involvement in the control of cyclin D1 or c-myc mRNA expression. p38 activity was weakly induced by CSF-1. No data were obtained to support a role for p38 or JNK-1 in BMM apoptosis resulting from CSF-1 withdrawal.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- Bone marrow-derived macrophages (BMM) were obtained by culturing bone marrow cells from femurs of CBA mice in the presence of CSF-1, as described previously (21). Cells were cultured in RPMI, 15% fetal bovine serum (FBS), 30% L-cell-conditioned medium (a source of CSF-1), routinely growth-arrested by washing three times in phosphate-buffered saline, and then cultured in RPMI, 10% FBS for 18 h or for times indicated.

Immunoprecipitations and Kinase Assays-- Cells were cultured and stimulated as described in the text, then lysates were prepared using a Triton-based lysis buffer supplemented with protease and phosphatase inhibitors (11). Extracts were precleared with 20 µl of protein A-Sepharose, and samples containing equal protein were immunoprecipitated at 4 °C overnight with 0.8 µg/ml anti-ERK-1 or anti-JNK-1 antibody or with 17 µg/ml anti-p38 antibody. Immune complexes were collected using 20 µl of protein A-Sepharose and washed with 4 × 1 ml of Triton-based lysis buffer (plus phosphatase inhibitors) and 1 × 1 ml of kinase assay buffer. ERK-1 kinase assays were performed as described elsewhere (11). p38 kinase assays were performed in 10 µl of 25 mM Hepes, pH 7.4, 10 mM MgC12, 1 mM vanadate, 20 mM NaF, 0.5 mg/ml myelin basic protein, [gamma -32P]ATP (adjusted to a specific activity of 3.7 × 108 MBq/mol). JNK-1 assays were performed after the addition of 10 µl of assay mix (without myelin basic protein) and 10 µl of c-Jun (1-169)-GST-agarose conjugate. Reactions were for 30 min at 30 °C and terminated by the addition of SDS sample buffer. Reaction mixtures were resolved by SDS-polyacrylamide gel electrophoresis, and the relative extent of substrate phosphorylation was determined using a Fujix BAS1000 phosphorimager.

The above antibodies were tested for specificity in our system by carrying out immunoprecipitations using BMM lysates and immunoblotting with the other MAP kinase antibodies. By this criterion, none of the antibodies cross-reacted with members of the other MAP kinase families studied. The measured ERK-1 and p38 activities were proportional to lysate protein concentration and linear over 30 min. The JNK-1 activity immunoprecipitated under the conditions used was dependent on, but not strictly proportional to, lysate concentration and was completely abolished by 0.4 µg/ml peptide used as epitope to raise the antibody.

Western Analysis-- Cell extracts in Triton-based lysis buffer containing equal amounts of protein were resolved by SDS-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose in 25 mM Tris, 192 mM glycine, 20% (v/v) methanol, and membranes were blocked for 1 h with 5% nonfat milk in Tris-buffered saline containing 0.5% Triton X-100 (TBST). Membranes were probed with relevant antibodies at 1:1000 in 0.5% nonfat milk, TBST, washed extensively with TBST, and probed with swine-anti-rabbit horseradish peroxidase (1:10000) in 0.5% milk, TBST. Bound secondary antibody was detected by enhanced chemiluminescence.

Protein Determinations-- Protein content of cell extracts was determined by the method of Lowry following coprecipitation of protein with 0.5% sodium deoxycholate using defatted bovine serum albumin as standard.

Apoptosis in BMM Cultures-- 3 × 106 cells/time point were lysed in 360 µl of 0.6% SDS, 0.1% EDTA (pH 8.0) and incubated at room temperature for 10 min, 21 µl of 5 M NaC1 was added, and the lysate was incubated at 4 °C overnight. The low molecular weight DNA was extracted (22) and analyzed by 2% agarose gel electrophoresis. Any apoptosis indicated by DNA laddering was confirmed by the terminal deoxynucleotidyltranserase-mediated dUTP nick end labeling (TUNEL) assay and characteristic apoptotic morphology as described previously (23).

DNA Synthesis and Cell Viability-- Tritiated thymidine ([3H]TdR) incorporation was used as a measure of DNA synthesis as before (24). To measure cell viability, BMM were cultured in 24-well plates in RPMI, 10% FBS or RPMI, 15% FBS, 30% L-cell-conditioned medium. Inhibitors were added at indicated concentrations using Me2SO as a vehicle at a final concentration of 0.5% (v/v). No effect on survival or DNA synthesis was noted with Me2SO at this concentration. Viable cell numbers were then determined by incubation of cultures for 2 h in the presence of MTT (0.8 mg/ml). Reduced MTT dye was solubilized overnight by the addition of 0.5 volumes of acidified 15% Triton X-100, and the amount was assessed at 595 nm using a Bio-Rad model 450 microplate reader.

mRNA Levels-- Approximately 1 × 107 cells/extraction were used. Cells were lysed in 600 µl of RNA extraction buffer (5 M guanidine thiocyanate, 10 mM Tris pH 7.6, 10 mM EDTA), and RNA was extracted and probed as described before (24). cDNA probes to either c-myc, v-fos, or cyclin D1 were radiolabeled with [alpha -32P]dATP (Bresatec) using nick translation and used to probe the blots. Control hybridization with a beta 2-microglobulin probe was used to determine RNA loading and quality.

Cytokines and Other Reagents-- Human recombinant CSF-1 was a gift from Chiron Corp. (Emeryville, CA). Other reagents used were from the following commercial sources: LPS, purified from Escherichia coli strain 0111:B4, Difco; myelin basic protein, Sigma; [methyl-3H]thymidine (3Mbq/mmol), Hybond C nitrocellulose, Enhanced Chemiluminescence (ECL) Western blotting detection reagents and Hyperfilm-ECL, Amersham Pharmacia Biotech; stabilized [gamma -32P]ATP (148 TBq/mmol), Bresatec (Adelaide, Australia.); protease inhibitors, Roche Molecular Biochemicals. c-Jun-GST fusion protein was expressed in E. coli, strain MC1061, and purified by glutathione agarose chromatography. cDNA probes were as before (24, 25).

Antibodies and Inhibitors-- The following antibodies were used for immunoprecipitations and in the kinase assays: anti-ERK-1 (C-16, Santa Cruz Biotechnology), anti-p38/CSBP (obtained from J. C. Lee; recognizing both CSBP1 and CSBP2). The following antibodies were used for Western blotting: anti-ERK (K23 (Santa Cruz), which recognizes both ERK-1 and -2), anti-JNK-1 (C17; Santa Cruz), and anti-phosphorylated ERK (New England Biolabs, which recognizes both pERK-1 and pERK-2). SB203580 (lot AJK-19080-74) and SKB202190 (lot 10148-25A) were gifts from Smith Kline Beecham (King of Prussia, PA) and Amgen Inc. (Boulder, CO), respectively. Secondary antibody-horseradish peroxidase conjugates were from DAKO (Glostrup, Denmark). PD98059 was from New England Biolabs Inc, Beverly, MA).

LPS Contamination of Culture Media and Reagents-- All practical precautions were taken for minimizing endotoxin contamination. Media and cytokines were made using pyrogen-free water (Delta West Pty Ltd., Bentley, Western Australia), and endotoxin levels in media and cytokines were routinely monitored using the Limulus lysate assay (Commonwealth Serum Laboratories, Parkville, Australia).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

ERK Activity in Cycling and Noncycling BMM-- We have previously shown that addition of CSF-1 to noncycling BMM causes an increase in ERK-1 and ERK-2 activities with a peak activity at around 5 min (11). We now show in Table I that cycling BMM, i.e. BMM maintained in the presence of saturating concentrations of CSF-1, have an approximately 2-fold higher ERK-1 activity than factor-deprived BMM, suggesting that the large and transient increase measured when growth-arrested cells are stimulated by CSF-1 ( Ref. 11 and Table I) is paralleled by an elevated level of activity in cycling versus growth-arrested BMM. LPS also stimulates ERK-1 activity in BMM via a kinetically distinguishable pathway (11). The activity of ERK-1 15 min after stimulation of growth-arrested cells with LPS is also shown for comparison. The observation that CSF-1-deprived BMM have a lower ERK-1 activity than cycling cells was verified by measuring the kinetics of loss of ERK-1 activity after CSF-1 withdrawal (Fig. 1a). In other experiments, we found that the level of ERK activity per unit cell protein was maintained between 24 and 36 h after withdrawal of CSF-1 from the culture medium (data not shown). It should be noted that in these experiments the ERK-1 activities were measured in lysate samples containing equal amounts of protein; furthermore, we verified that the ERK-1 activity was not affected by cell density in these experiments because a similar activity was measured in cycling cultures harvested at the beginning and at the end of the 18-h period (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Relative ERK-1 activities in BMM
Lysates were prepared from exponentially growing BMM cultures (Cycling), from cultures that were growth-arrested by 18 h of incubation in RPMI, 10% FBS (growth-arrested), and from the growth-arrested population stimulated with CSF-1 (5000 units/ml) or LPS (100 ng/ml) for 5 min and 15 min, respectively. 50 µg of precleared lysates were immunoprecipitated and assayed for ERK-1 activity ("Experimental Procedures"). Kinase activities are expressed relative to that found in cycling cells, and the data are mean values (±S.E.) for triplicate determinations.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   ERK-1 activity and apoptosis following CSF-1 removal from BMM. a, ERK-1 activity. Cycling BMM cultured in 10-cm dishes were washed three times to remove CSF-1 and then transferred to RPMI, 10% FBS for the indicated times. ERK-1 activity was measured in cell lysates as in Table I. Kinase activity is expressed relative to that found in cycling cells; the data are expressed as mean values (±S.E.) for triplicate determinations and are representative of three independent experiments. b, apoptosis. Cycling BMM in 10-cm dishes were washed three times to remove CSF-1 and then transferred to RPMI, 10% FBS for 24 h. DNA was extracted from the cycling (t = 0) and CSF-1-deprived populations and analyzed by agarose gel electrophoresis ("Experimental Procedures"). Gels were stained with ethidium bromide and photographed under UV light.

It is generally assumed that removal of growth factor from hemopoietic cells leads to cell death via apoptosis (26). We found that removal of CSF-1 from cycling BMM led to cell death accompanied by the DNA laddering that is often characteristic of apoptosis (Fig. 1b). We also observed apoptotic macrophages within phagolysosomes of neighboring cells, which is to be expected given the known phagocytic activity of macrophages toward cells undergoing apoptosis. This removal makes quantitation of apoptotic BMM in such cultures difficult; however, quantitation of cells possessing the morphologic and histological characteristics of late stage apoptosis both by bisbenzimide or TUNEL staining ("Experimental Procedures") indicated that there were approximately 0.3% apoptotic BMM in cycling BMM cultures with this proportion increasing to 8-10% after 24 h of growth factor removal (data not shown). These data indicate that at least a proportion of the CSF-1-deprived BMM are dying via an apoptotic pathway.

It has previously been shown in nerve growth factor-treated PC-12 cells, for example, that growth factor withdrawal results in loss of ERK activity and cell death by apoptosis, leading to the suggestion that ERK activity is important for growth factor-mediated cell survival (14, 27). A specific inhibitor of MEK activation, PD98059, is widely used to determine the relevance of a MEK/ERK pathway to cellular function (28); we have found previously that a 30-min preincubation of BMM with this compound before stimulation with CSF-1 inhibited the activation of both ERK-1 and ERK-2 with an IC50 of 5-10 µM (Ref. 12 and data not shown). We therefore determined whether PD98059 would reverse the ability of CSF-1 to suppress apoptosis in BMM. However, it can be seen in Fig. 2 that the inhibitor of MEK activation did not do this, suggesting that ERK activity per se is not critical for the maintenance of BMM viability by CSF-1. In support of this we also found that incubation of BMM with 50 µM PD98059 did not accelerate the loss of viability (measured using MTT dye reduction) following CSF-1 withdrawal (data not shown).


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of PD98059 and 8BrcAMP on the reversal of BMM apoptosis by CSF-1. Low molecular weight DNA was isolated from growth-arrested BMM restimulated for 24 h with CSF-1 (5000 units/ml) in the absence or presence of PD98059 (50 µM), 8BrcAMP (1 mM), or their combination, as indicated. DNA was separated by electrophoresis on a 2% agarose gel then visualized by UV light and photographed. The figure is a representative of four separate experiments.

We also examined the effect of 8BrcAMP, an agent that can suppress a number of CSF-1-induced responses in BMM while activating the ERK activity (12, 24). We see in Fig. 2 that 8BrcAMP by itself cannot prevent the reversal of apoptosis by CSF-1 but interestingly, when added with PD98059, can do so. This finding suggests that multiple pathways may be governing the maintenance of BMM viability by CSF-1 and that at least one of these pathways is ERK-dependent (see below).

We have found previously that expression of ERK activity in BMM in response to a particular stimulus did not always correlate with the subsequent appearance of a DNA synthesis response (11). This observation does not necessarily mean that ERK activity is not required for DNA synthesis to occur in BMM, especially because we have shown above (Table I; Fig. 1a) that ERK-1 activity in cycling BMM was higher than that in CSF-1-deprived cells. To test this possibility directly we examined the effect of PD98059 on DNA synthesis in CSF-1-treated BMM. We see in Table II that PD98059 inhibited CSF-1-stimulated DNA synthesis in BMM measured 20 h after the addition of both CSF-1 and the inhibitor to growth-arrested BMM, suggesting that a MEK/ERK pathway may play a role in DNA synthesis control in this system.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of PD98059 on CSF-1-stimulated BMM DNA synthesis
Growth-arrested BMM (control) were treated with CSF-1 (5000 units/ml) in the absence or presence of PD98059 (50 µM). DNA synthesis was measured by pulsing cells with [3H]TdR at 20 h and harvesting at 22 h ("Experimental Procedures"). Values are means of quadruplicate cultures (±S.D.) and are from a representative experiment that was repeated four times.

MEK/ERK-dependent Pathways in CSF-1-treated BMM-- Previous studies in CSF-1-treated macrophages have examined the pathways governing CSF-1-dependent activation of ERK activity (29, 30); pathways downstream of the enhanced ERK activity that may be involved in, for example, the control of BMM DNA synthesis by CSF-1 have not been widely examined. Much evidence has implicated both cyclin D1 and c-Myc as important regulators of the mammalian cell cycle (31), including in CSF-1-treated macrophages (25, 32-34); cyclin D1 and c-myc transcription have been shown to be dependent upon upstream ERK activity in a number of cell systems, including CSF-1-stimulated NIH3T3 cells ectopically expressing c-Fms (see Ref. 10 and references therein). We therefore examined whether PD98059 suppresses cyclin D1 and c-myc mRNA expression as part of its inhibitory action in controlling CSF-1-stimulated BMM DNA synthesis. Our data, however, show that PD98059, even at concentrations as high as 100 µM, failed to inhibit the increase in cyclin D1 and c-myc mRNA expression resulting from stimulation of BMM with CSF-1 (Fig. 3a); in contrast, 8BrcAMP did, as we and others have previously reported (33-35). These results contrast with our earlier findings that CSF-1-stimulated c-fos mRNA expression was inhibited by PD98059 (Fig. 3b (12)). These data suggest that a MEK/ERK pathway does not govern CSF-1 stimulated cyclin D1 mRNA and c-myc mRNA expression in macrophages and that regulation of the levels of these mRNA species is different from that found in CSF-1-stimulated NIH 3T3 cells (10) (see "Discussion"). The above data indicate that, unlike 8BrcAMP, PD98059 does not suppress cyclin D1 or c-myc mRNA expression as part of its mechanism in inhibiting DNA synthesis in CSF-1 treated BMM.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of inhibitors of ERK and p38 pathways on CSF-1-stimulated mRNA expression. a, total RNA was isolated from growth-arrested BMM or from BMM restimulated for 6 h with CSF-1 (5000 units/ml) in the absence or presence of PD98059 (100 µM) or 8BrcAMP (1 mM), as indicated. The three autoradiograms represent the same Northern blot hybridized successively with radiolabeled cDNA fragments of cyclin D1, c-myc, and (as a control for RNA loading) beta 2-microglobulin. b, total RNA was isolated from CSF-1-deprived BMM or from BMM restimulated for 30 min with CSF-1 (5000 units/ml) in the absence or presence of PD98059 (100 µM) or SB202190 (10 µM), as indicated. The two autoradiograms represent the same Northern blot hybridized successively with radiolabeled cDNA fragments of c-fos and beta 2-microglobulin, the latter as a control for RNA loading.

p38 Activity in Cycling and Noncycling BMM-- p38 activity has been implicated in the control of cytokine biosynthesis in LPS-stimulated monocytes/macrophages (18). Activation of p38 by CSF-1, measured by its tyrosine phosphorylation status on a Western blot, has recently been reported in a murine myeloid cell line (17). Given the evidence that CSF-1 is a poor stimulator of monocyte/macrophage inflammatory cytokine production when compared with LPS (Ref. 20 and references cited in Ref. 19), we decided to compare p38 activity directly in BMM stimulated with CSF-1 and, as a comparison, LPS. For this purpose we used a quantitative immunoprecipitation kinase assay ("Experimental Procedures"). Our data (Fig. 4a) show that cycling BMM have about a 2-fold higher p38 activity than CSF-1-deprived cells and that when added back, CSF-1 is a relatively weak activator of p38 compared with LPS. This contrasts with the activation of ERK-1 (and ERK-2) in macrophages, where we have shown that CSF-1 and LPS activate this enzyme to similar extents (Table I and Ref. 11). The kinetics of activation of p38 by LPS and CSF-1 are different, with LPS activation being maximal at 15 min whereas the small amount of activation observed with CSF-1 peaks earlier at around 5 min (data not shown). These time courses are identical to those that we have observed previously for ERK activation by these stimuli (11).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   p38 activity in BMM and its lack of involvement in apoptosis. a, lysates were prepared from exponentially growing cultures, from cultures that were growth factor-deprived by an 18-h incubation in RPMI, 10% FBS, and from the CSF-1-deprived cells stimulated again with CSF-1 (5000 units/ml) or with LPS (100 ng/ml) for 5 min and 15 min, respectively. 100 µg of precleared lysates were immunoprecipitated and assayed for p38 activity ("Experimental Procedures"). The degrees of substrate (myelin basic protein (MBP)) phosphorylation in single lanes of acrylamide gels are shown. Kinase activities are expressed relative to those found in cycling cells (arbitrarily given a value of 1), and the values shown are means (±S.E.) from triplicate determinations. b, cycling BMM were washed three times to remove CSF-1 and then transferred to RPMI, 10% FBS for the indicated times. Lysate aliquots containing 100 µg of protein were assayed for p38 activity as in a, and kinase activities are expressed relative to those found in cycling cells; the data are expressed as mean values (±S.E.) from triplicate determinations and are representative of three independent experiments. c, CSF-1 was withdrawn from cycling BMM, which were then either untreated () or treated (open circle ) with 10 µM SKB202190 in 2% v/v Me2SO at the same time as CSF-1 withdrawal. Viable cell numbers were determined using a MTT reduction assay ("Experimental Procedures"). Data are mean values (±S.E.) from triplicate cultures and are representative of two experiments.

In PC-12 cells, a 2-3-fold elevation in p38 activity preceded the onset of apoptosis after nerve growth factor withdrawal (14). We therefore followed p38 activity in macrophages deprived of CSF-1 over an 18-h period, a time frame in which, given the time of onset of apoptosis in BMM (Fig. 1b), we might expect by analogy (14) to see increases in p38 activity. We show, however, that there is no significant elevation of p38 activity following CSF-1 withdrawal from cycling BMM (Fig. 4b). Similar results were obtained using the CSF-1-dependent macrophage cell line, BAC1.2F5 (data not shown). In BMM, no elevation in the p38 activity was noted if its activity was monitored between 30 min and 3 h after CSF-1 removal (data not shown). What we found instead is a loss of p38 activity compared with the value for the cycling cells. It should be noted that the p38 activities are expressed relative to cell protein in each lysate and that they were not affected by cell density in these experiments because similar activities were measured in cycling cultures harvested at the beginning and at the end of the 18-h period (data not shown). Therefore, for both primary cultures of macrophages and a CSF-1-dependent macrophage cell line, withdrawal of CSF-1 results in a decrease in p38 activity with no indication of the involvement of p38 activation in the cell death that occurs when the CSF-1 is removed.

To further test the above conclusion, we examined the effect of specific inhibitors of this kinase on BMM survival. The phenolic triaryl imidazole derivatives SB203580 and SKB202190 have been shown to inhibit cytokine production in human monocytes by binding selectively to and inhibiting the enzymatic activity of p38 (18, 36); they have been widely used in the investigation of the biological functions of p38 (28). As a prelude to studying their effects on macrophage survival, we tested the inhibitory activity and selectivity of these compounds against p38 versus ERK-1 isolated from murine macrophages. SKB202190 strongly inhibited p38 activity immunoprecipitated from BMM with an IC50 of about 45 nM (data not shown). By contrast, there was no effect on ERK-1 activity at concentrations as high as 0.5 µM. Although the IC50 for the inhibition of murine p38 was slightly higher than the 10 nM reported for human p38, there is still a strong selectivity with respect to the murine p38 member(s) of the MAP kinase family. This result also confirms the specificity of the kinase assays used above ("Experimental Procedures"). The effect of SKB202190 on BMM survival was assessed using an MTT dye reduction assay. No significant effect on loss of viability induced by CSF-1 withdrawal, assessed by MTT dye reduction, was observed when the macrophages were cultured for up to 2 days in the presence of 10 µM SKB202190 (Fig. 4c). Similar results were obtained using SB203580 where we measured in vitro an IC50 for murine p38 of about 20 nM (data not shown). These data reinforce the conclusion arrived at above that p38 activity is not required for macrophage cell death under conditions of growth factor deprivation. When the BMM were cultured in the presence of SKB202190, administered under the same conditions as the viability experiments, the cells became highly vacuolated after 24 h, consistent with a role for p38 in osmoregulation and indicating that, although viability was not significantly affected, the drug is still active throughout the time frame of the experiment.

Because cycling BMM have approximately 2-fold higher p38 enzymatic activity per unit cell protein than growth-arrested BMM (Fig. 4a), we measured the effect of SKB202190 on BMM DNA synthesis. The data presented in Fig. 5 show that there was an inhibitory effect of this compound on the incorporation of [3H]TdR into DNA. This effect was consistently observed at relatively high concentrations, and in five independent experiments, inhibition of [3H]TdR incorporation occurred with an IC50 of 4-5 µM. This high IC50 is comparable with what has been reported for DNA synthesis inhibition in other murine cell lines (37). We found that SKB202190 (5 µM) did not prevent the CSF-1-induced increase in c-fos mRNA expression measured 30 min after CSF-1 addition to growth-arrested BMM (Fig. 3b); in fact there appeared to be a slight increase in the c-fos mRNA levels. The suppressive effect of PD98059 on c-fos mRNA induction, found previously (12), is shown for comparison. However, in preliminary experiments, we found that the addition of 5 µM SB202190 resulted in a decrease in CSF-1-dependent induction of c-myc mRNA, measured at 6 h, with no effect noted on cyclin D1 mRNA levels measured at the same time (not shown).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of SKB202190 on BMM DNA synthesis. CSF-1-deprived (growth-arrested) BMM cultures in 96-well plates were stimulated with CSF-1 (5000 units/ml) (solid bars) or left without CSF-1 (open bars) in the absence or presence of the indicated concentrations of SKB202190. DNA synthesis was measured by pulsing cells with [3H]TdR at 20 h and harvesting the cells at 22 h. Data represent means ±S.E. of quadruple determinations in a typical experiment that was repeated a further four times.

JNK-1 Activity in BMM-- Enhanced JNK-1 activity has also been implicated in apoptosis; for example, in that found in PC-12 cells following nerve growth factor removal (14). JNK-1 activity was not detected in BMM from which the CSF-1 had been removed nor after its readdition for 5 min (data not shown), although robust activation by 100 ng/ml LPS and TNFalpha (used as positive controls) was detected. No statistically significant activity was measurable in cycling BMM, and as for the p38 activity upon CSF-1 removal, no increase was detectable over a 30-min-24 h period (n = 3; data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the above studies we tested the effects on BMM functions of PD98059, a highly specific inhibitor of MEK activation widely used to determine the involvement of a MEK/ERK pathway in particular cell functions (28). In general, an inhibitor of an intracellular target, even though it may not be exquisitely specific, can provide evidence that is consistent with a role for its target in a particular cellular response (for example, to a growth factor); if its action is very effective on its target but does not affect a particular cellular response, then it is likely that the target of the inhibitor is not required for that response. We have demonstrated above that ERK-1 activity is maintained at a higher level in cycling BMM than in cells from which the CSF-1 was removed (Table I; Fig. 1a) but, using PD98059, no evidence could be found for its involvement in the CSF-1-stimulated enhancement of BMM survival (i.e. reversal of apoptosis) (Fig. 2). Even though enhanced BMM ERK activity does not correlate with enhanced DNA synthesis (11, 12) because, for example, a nonmitogenic stimulus such as LPS can enhance ERK activity, PD98059 suppressed somewhat the CSF-1-stimulated BMM DNA synthesis (Table II); assuming that PD98059 is specific for the ERK pathway under the conditions used (28), this suppression suggests MEK/ERK involvement in a pathway(s) critical for the progression into S-phase in this system. The elevated ERK activity in cycling BMM is consistent with this conclusion and suggests that ERK activation may be necessary but not sufficient for macrophage proliferation.

In a number of other cell systems, it is widely concluded that enhanced ERK activity leads to transcription of cyclin D1 and c-myc genes with subsequent progression into S phase. However, in CSF-1-stimulated BMM we did not find that PD98059 inhibited cyclin D1 mRNA or c-myc mRNA expression (Fig. 3a), observations at odds with other systems including CSF-1-stimulated NIH 3T3 cells, which had been transfected with the CSF-1R, c-fms (Ref. 10 and references therein). Interestingly, when the induction of cyclin D1 protein was monitored by Western blotting, we found in preliminary experiments that PD98059 (>= 50 µM) did suppress it (data not shown). Because PD98059 blocked CSF-1-induced c-fos mRNA expression (Ref. 12; Fig. 3b), it is possible that a MEK/ERK/c-Fos-dependent pathway is relevant for DNA synthesis control in CSF-1-treated BMM; of possible relevance also is the recent report that persistent ERK activation by CSF-1 is necessary for both expression and post-translational activation of ets-2 in macrophages (30).

The actions of PD98059 differ from those of another inhibitor of CSF-1-stimulated BMM DNA synthesis, albeit a more potent one, namely 8BrcAMP (12). This cAMP analogue blocked the CSF-1-stimulated cyclin D1 and c-myc mRNA expression (Refs. 25 and 34; Fig. 3a) while raising c-fos mRNA expression and ERK activity (12, 24). However, 8BrcAMP, like PD98059, could not prevent the reversal of BMM apoptosis by CSF-1 (Fig. 2); interestingly, the combination of the two agents did so, suggesting perhaps they control complementary pathways emanating from the stimulated CSF-1 receptor, which are each important for cell survival and possibly for other cellular responses. We have found before that 8BrcAMP inhibited CSF-1-induced Ras activity (12), raising once again the possibility of the presence of a Ras-independent pathway controlling ERK activity in macrophages (5); perhaps enhanced Ras activity but not ERK activity is relevant for subsequent cyclin D1 mRNA or c-myc mRNA expression in CSF-1-stimulated macrophages.

p38 MAP kinase has been shown in a variety of cell systems to be strongly activated by stress signals such as osmotic shock, UV light, LPS, and inflammatory cytokines but to be activated only weakly by growth factors (see Refs. 13 and 27 for reviews). p38 is known to be involved in the control of cytokine production (e.g. TNFalpha in LPS-activated macrophages (18)). Some reports but not others have found that CSF-1 is a relatively poor stimulator of inflammatory cytokine synthesis (e.g. TNFalpha , interleukin-1) in monocytes/macrophages in vitro (19, 20, 38-40). However, it has been reported that CSF-1 causes an increase in tyrosine phosphorylation in p38 immunoprecipitates in the myeloid cell line, FD-MACII cells (17). This type of analysis does not measure enzymatic activation nor give any indication as to the degree of activation of this enzyme. We therefore decided to measure p38 activity by a specific and quantitative immunoprecipitation kinase assay in cultures of primary macrophages and to compare directly the activity induced by CSF-1 treatment to that resulting from the action of LPS. Our data show that in BMM the stimulation by CSF-1 of p38 enzymatic activity is very small compared with that stimulated by LPS (Fig. 4a) and is kinetically distinguishable from the latter (data not shown). These findings are entirely consistent with the reports from our laboratory and those of others that show that CSF-1 is a weak stimulator of cytokine biosynthesis in monocytes and macrophages compared with LPS and offer an explanation for these findings. The kinetics of p38 activation by CSF-1 and LPS are similar to those that we, and others, have previously observed for ERK-1 activation in the same cells and by the same stimuli (11), although there are clear differences in the extent of activation. Thus CSF-1 activates both enzymes maximally at 5 min in growth-arrested cells, whereas LPS activates them maximally at 15 min; furthermore, LPS is a strong activator of both MAP kinase family members, whereas CSF-1 is a weak activator of the p38 enzyme relative to its effects on the ERK isoforms. Whether the activation of these enzymes by CSF-1 and LPS represents activation of the same intracellular pools is not clear, but in this context it is of interest that a recent report has shown that LPS preferentially activates a minor microtubule-bound subpopulation of MAP kinase (41).

The p38 pathway has been implicated to play a critical role in apoptosis, because many apoptotic signals are able to stimulate p38 activity, and p38 activation is correlated with the induction of apoptosis in several cell types (14-16); however, others have found no correlation between its activation and apoptosis in other cell types and even found some activation by growth factors (see for example Refs. 17, 42). Inhibition of p38 activity has been shown to suppress apoptosis in some cases (see for example Ref. 16) but not in others (43) and to even induce apoptosis (44). In BMM (Fig. 4b) and the macrophage cell line BAC.1.2F5 (data not shown), we found a gradual decrease in p38 activity following CSF-1 withdrawal; furthermore, SKB202190 failed to inhibit the decrease in BMM viability (Fig. 4c). Our data, therefore, do not support a role for p38 family members, at least those that are susceptible to pyridinyl imidazole inhibition, in macrophage cell death resulting from growth factor deprivation and indicate that CSF-1 does not maintain cell viability by suppressing p38 activity. The significance of the elevated p38 activity in cycling BMM awaits clarification. p38 activity may play a permissive role in CSF-1-driven macrophage proliferation because SKB202190 blocked CSF-1-stimulated BMM DNA synthesis, and our preliminary data suggest that it inhibits the induction of c-myc mRNA but not cyclin D1 mRNA; however, it should be noted that the concentrations required were much higher than those needed to inhibit the in vitro BMM p38 activity, suggesting that the drug might have alternative targets in BMM at the higher concentrations.

JNK activity in various cell types can be enhanced by a similar range of stress signals as p38 activity and be weakly activated by growth factors (13). We could find no evidence for an activation of JNK-1 activity in CSF-1-treated BMM above the very low levels found in the untreated population. In contrast, LPS and TNFalpha both gave significant increases; LPS has been shown previously to stimulate JNK activity in macrophages (45). In BMM we found no detectable increase in JNK activity as they proceeded to the apoptotic state and, therefore, no support for its role in the control of apoptosis in these cells.

In summary, the lack of association of MAP kinase family members with apoptosis and/or survival in the macrophages again highlights the need to explore the relevance of a signaling pathway to cellular function for each particular cell type; also, the atypical evidence presented above that ERK activity may not be controlling cyclin D1 mRNA and c-myc mRNA expression in CSF-1-stimulated BMM but does so in CSF-1-treated NIH 3T3 cells (cf. present paper and Ref. 10) again indicates that CSF-1 biology and associated signal transduction pathways are best studied in myeloid cells (5). The relatively weak stimulation of p38 activity by CSF-1 compared with that resulting from LPS action contrasts some actions of CSF-1 (a survival and growth factor) with those of LPS (a stress stimulus) and is consistent with some reports (19, 20), but not others (38-40), showing that CSF-1 is a relatively poor stimulator of monocyte/macrophage inflammatory mediator production.

    ACKNOWLEDGEMENTS

We thank R. Sallay and A. Markham for typing the manuscript.

    FOOTNOTES

* This work was supported by a program grant from the National Health and Medical Research Council of Australia.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Macfarlane Burnet Centre for Medical Research, P. O. Box 254, Fairfield, Victoria 3078, Australia. Tel.: 61-3-9282-2127; Fax: 61-3-9282-2100; E-mail: anthonyj{at}burnet.edu.au.

    ABBREVIATIONS

The abbreviations used are: CSF-1, colony stimulating factor-1; BMM: bone marrow-derived macrophages, LPS, lipopolysaccharide; TNF, tumor necrosis factor; ERK, extracellular signal-regulated kinase; p38/CSBP, cytokine suppressive anti-inflammatory drug-binding protein (also known as reactivating kinase); JNK, c-Jun N-terminal kinase; MAP kinase, mitogen-activated protein kinase; MEK, MAP-ERK kinase; MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; FBS, fetal bovine serum; TBST, Tris-buffered saline containing 0.5% Triton X-100; TUNEL, terminal deoxynucleotidyltranserase-mediated dUTP nick end labeling; 8BrcAMP, 8-bromo-cAMP; GST, glutathione S-transferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Tushinski, R. J., Oliver, I. T., Guilbert, L. J., Tynan, W., Warner, J. R., and Stanley, E. R. (1982) Cell 28, 71-81[Medline] [Order article via Infotrieve]
  2. Tushinski, R. J., and Stanley, E. R. (1983) J. Cell. Physiol. 116, 67-75[Medline] [Order article via Infotrieve]
  3. Pollard, J. W., Morgan, C. J., Dello Sbarba, P., Cheers, C., and Stanley, E. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1474-1478[Abstract]
  4. Dello Sbarba, P., Pollard, J. W., and Stanley, E. R. (1991) Growth Factors 5, 75-85[Medline] [Order article via Infotrieve]
  5. Hamilton, J. A. (1997) J. Leukocyte Biol. 62, 145-155[Abstract]
  6. Roussel, M. F., Cleveland, J. L., Shurtleff, S. A., and Sherr, C. J. (1991) Nature 353, 361-363[CrossRef][Medline] [Order article via Infotrieve]
  7. Langer, S. J., Bortner, D. M., Roussel, M. F., Sherr, C. J., and Ostrowski, M. C. (1992) Mol. Cell. Biol. 12, 5355-5362[Abstract]
  8. Roussel, M. F., Theodoras, A. M., Pagano, M., and Sherr, C. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6837-6841[Abstract]
  9. L'Allemain, G. (1994) Prog. Growth Factor Res. 5, 291-334[Medline] [Order article via Infotrieve]
  10. Aziz, N., Cherwinski, H., and McMahon, M. (1999) Mol. Cell. Biol. 19, 1101-1115[Abstract/Free Full Text]
  11. Jaworowski, A., Christy, E., Yusoff, P., Byrne, R., and Hamilton, J. A. (1996) Biochem. J. 320, 1011-1016[Medline] [Order article via Infotrieve]
  12. Wilson, N. J., Jaworowski, A., Ward, A. C., and Hamilton, J. A. (1998) Biochem. Biophys. Res. Commun. 244, 475-480[CrossRef][Medline] [Order article via Infotrieve]
  13. Kyriakis, J. M., and Avruch, J. (1996) J. Biol. Chem. 271, 24313-24316[Free Full Text]
  14. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326-1331[Abstract]
  15. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997) Science 275, 90-94[Abstract/Free Full Text]
  16. Kummer, J. L., Rao, P. K., and Heidenreich, K. A. (1997) J. Biol. Chem. 272, 20490-20494[Abstract/Free Full Text]
  17. Foltz, I. N., Lee, J. C., Young, P. R., and Schrader, J. W. (1997) J. Biol. Chem. 272, 3296-3301[Abstract/Free Full Text]
  18. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemans, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739-746[CrossRef][Medline] [Order article via Infotrieve]
  19. Hamilton, J. A. (1993) Immunol. Today 14, 18-24[Medline] [Order article via Infotrieve]
  20. Hamilton, J. A., Whitty, G. A., Stanton, H., and Meager, A. (1993) J. Leukocyte Biol. 53, 707-714[Abstract]
  21. Vairo, G., and Hamilton, J. A. (1985) Biochem. Biophys. Res. Commun. 132, 430-437[Medline] [Order article via Infotrieve]
  22. Hart, B. (1967) J. Mol. Biol. 26, 365-369[Medline] [Order article via Infotrieve]
  23. Messina, A., Jaworowski, A., and Bell, C. (1996) J. Comp. Neurol. 372, 544-550[CrossRef][Medline] [Order article via Infotrieve]
  24. Vairo, G., Argyriou, S., Bordun, A-M, Whitty, G., and Hamilton, J. A. (1990) J. Biol. Chem. 265, 2692-2701[Abstract/Free Full Text]
  25. Cocks, B. J., Vairo, G., Bodrug, S. E., and Hamilton, J. A. (1992) J. Biol. Chem. 267, 12307-12310[Abstract/Free Full Text]
  26. Williams, G. T., Smith, C. A., Spooncer, E., Dexter, T. M., and Taylor, D. R. (1990) Nature 343, 76-79[CrossRef][Medline] [Order article via Infotrieve]
  27. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
  28. Cohen, P. (1998) Trends Cell Biol. 7, 353-361[CrossRef]
  29. Buscher, D., Hipskind, R. A., Krautwald, S., Reimann, T., and Baccarini, M. (1995) Mol. Cell. Biol. 15, 466-475[Abstract]
  30. Fowles, L. F., Martin, M. L., Nelsen, L., Stacey, K. J., Redd, D., Clark, Y. M., Nagamine, Y., McMahon, M., Hume, D. A., and Ostrowski, M. C. (1998) Mol. Cell. Biol. 18, 5148-5156[Abstract/Free Full Text]
  31. Zornig, M., and Evan, G. I. (1996) Curr Biol 6, 1553-1556[Medline] [Order article via Infotrieve]
  32. Matsushime, H., Roussel, M. F., Ashmun, R. A., and Sherr, C. J. (1991) Cell 65, 701-713[Medline] [Order article via Infotrieve]
  33. Vairo, G., Vadiveloo, P. K., Royston, A. K., Filonzi, E. L., Rockman, S. P., Rock, C. O., Jackowski, S., and Hamilton, J. A. (1995) Oncogene 10, 1969-1976[Medline] [Order article via Infotrieve]
  34. Vadiveloo, P. K., Vairo, G., Novak, U., Royston, A. K., Whitty, G., Filonzi, E. L., Cragoe, E. J., Jr., and Hamilton, J. A. (1996) Oncogene 13, 599-608[Medline] [Order article via Infotrieve]
  35. Rock, C. O., Cleveland, J. L., and Jackowski, S. (1992) Mol. Cell. Biol. 12, 2351-2358[Abstract]
  36. Lee, J. C., Badger, A. M., Griswold, D. E., Dunnington, D., Truneh, A., Votta, B., White, J. R., Young, P. R., and Bender, P. E. (1993) Ann. N. Y. Acad. Sci. 696, 149-170[Medline] [Order article via Infotrieve]
  37. Crawley, J. B., Rawlinson, L., Lali, F. V., Page, T. H., Saklatvala, J., and Foxwell, B. M. (1997) J. Biol. Chem. 272, 15023-15027[Abstract/Free Full Text]
  38. Oster, W., Brach, M. A., Gruss, H. J., Mertelsmann, R., and Herrmann, F. (1992) Blood 79, 1260-1265[Abstract]
  39. Moore, R. N., Oppenheim, J. J., Farrar, J. J., Carter, C. S., Jr., Waheed, A., and Shadduck, R. K. (1980) J. Immunol. 125, 1302-1305[Abstract/Free Full Text]
  40. Evans, R., Duffy, T. M., Blake, S. S., and Lin, H. S. (1989) J. Leukocyte Biol. 46, 428-433[Abstract]
  41. Ding, A., Chen, B., Fuortes, M., and Blum, E. (1996) J. Exp. Med. 183, 1899-1904[Abstract]
  42. Nagata, Y., Moriguchi, T., Nishida, E., and Todokoro, K. (1997) Blood 80, 929-934
  43. Salmon, R. A., Foltz, I. N., Young, P. R., and Schrader, J. W. (1997) J. Immunol. 159, 5309-5317[Abstract]
  44. Nemoto, S., Xiang, J., Huang, S., and Lin, A. (1998) J. Biol. Chem. 273, 16415-16420[Abstract/Free Full Text]
  45. Hambleton, J., Weinstein, S. L., Lem, L., and DeFranco, A. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2774-2778[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.